Kyle Mikson CFA, an analyst from Canaccord Genuity, maintained the Buy rating on Quanterix (QTRX – Research Report). The associated price target remains the same with $12.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Kyle Mikson CFA has given his Buy rating due to a combination of factors that suggest potential growth for Quanterix. The company is actively working on its Alzheimer’s disease diagnostics, with plans to submit data to the FDA by the end of 2025 and potential reimbursement updates by mid-2025. These developments could significantly enhance Quanterix’s market position in the diagnostics field.
Kyle Mikson also notes the strategic merger with Akoya, expected to close in the third quarter of 2025, which could drive synergies and operational improvements. Additionally, recent insider share purchases indicate confidence in the company’s valuation. Despite macroeconomic challenges impacting near-term revenue, new product launches and the Akoya acquisition are expected to bolster Quanterix’s performance and valuation over time.
QTRX’s price has also changed dramatically for the past six months – from $11.110 to $6.140, which is a -44.73% drop .